7 news items
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
VKTX
4 Jun 24
compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative
Viking Therapeutics to Participate at Upcoming Investor Conferences
VKTX
30 May 24
expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2809, a novel
Ligand Reports First Quarter 2024 Financial Results
AMGN
CASI
JAZZ
7 May 24
the leadership of Scott Plesha as Chief Executive Officer. Pelthos is focused on the commercialization of innovative, safe, and efficacious therapeutic products
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
VKTX
24 Apr 24
research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
ATNM
AZN
BMY
18 Apr 24
biotech sector continues to benefit from favorable financing conditions and a vibrant outlook for mergers and acquisitions, coupled with innovative
30wg9kfwwecqmpa72c7t18cfasx10j8c89lsj0rv4x
VKTX
17 Apr 24
in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel
b6yu s7v46hdjg3geuoci0j
VKTX
26 Mar 24
activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical
- Prev
- 1
- Next